ImmunityBio, Inc. IBRX Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s operating lease liabilities (total)?
- ImmunityBio, Inc. (IBRX) reported operating lease liabilities (total) of $40.77M in Q1 2026.
- How has ImmunityBio, Inc.'s operating lease liabilities (total) changed year-over-year?
- ImmunityBio, Inc.'s operating lease liabilities (total) increased by 0.5% year-over-year, from $40.56M to $40.77M.
- What is the long-term trend for ImmunityBio, Inc.'s operating lease liabilities (total)?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s operating lease liabilities (total) has grown at a 21.8% compound annual growth rate (CAGR), from $15.31M to $40.98M.
- What does operating lease liabilities (total) mean?
- The total present value of all future payments the company is contractually obligated to make for operating leases.
- How do you interpret operating lease liabilities (total)?
- An increase suggests expanding physical footprint or long-term facility commitments, while a decrease may indicate lease expirations or downsizing. High levels relative to cash reserves can signal potential liquidity pressure.
- How does operating lease liabilities (total) compare across companies?
- Biotech peers typically maintain moderate lease liabilities aligned with their laboratory and office footprint requirements; high levels relative to R&D spend may indicate inefficient capital allocation.